Horizon Therapeutics (HZNP) Tops Q4 EPS by 12c

Horizon Therapeutics (NASDAQ: HZNP) reported Q4 EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942 million versus the consensus estimate of $922.92 million.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c